digital health startups weight loss glp-1 👎 The startup making look bad Startups, big players ramp up

The ruling will reshape the regulatory landscape and impact the future of Hims & Hers Health (NYSE: $HIMS), one of the fastest-growing and most controversial players

Revising it for intellectual content: C

Most plans reach a fraction, typically up to about 25%, of a standard GLP-1 maintenance dose

Pricing transparency: How does your PBM provide visibility into the true cost of medications (ingredient cost, dispensing fees, and PBM administrative fees) under a direct or pass-through pricing model

Additionally, GLP-1 has been shown to enhance the proliferation and differentiation of endothelial progenitor cells through upregulation of VEGF, potentially promoting angiogenesis that could contribute to retinal complications [101,102]